Related Experiment Video
Updated: Aug 6, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
Impact of pharmacogenetics on aspirin resistance: a systematic review
Gustavo Figueiredo da Silva1, Bruno Mattei Lopes1, Vinicius Moser1
1Universidade da Região de Joinville, Departamento de Medicina, Joinville SC, Brazil.
Insights
Genetic variants impact aspirin resistance (AR), affecting cardiovascular disease (CVD) treatment. Further research is needed to understand these pharmacogenetic associations for improved patient outcomes.
Area of Science:
- Pharmacogenetics
- Cardiovascular Disease Research
- Genetics and Medicine
Background:
- Pharmacogenetics offers improved disease management, particularly for cardiovascular disease (CVD).
- Acetylsalicylic acid (aspirin) is crucial for CVD prevention by inhibiting platelet aggregation.
- Genetic variations can lead to aspirin resistance (AR), causing treatment failure in some patients.
Conclusions:
- Pharmacogenetics is a rapidly advancing field with significant potential.
- Further research is essential to elucidate the complex associations between genetic variants and aspirin resistance.
- Understanding these genetic factors can lead to more personalized and effective CVD prevention strategies.
Background:
Pharmacogenetics promises better control of diseases such as cardiovascular disease (CVD). Acetylsalicylic acid, aspirin, prevents the formation of an activating agent of platelet aggregation and vasoconstriction, and it is used to prevent CVD. Nevertheless, patients may have treatment failure due to genetic variants that modify the metabolism of the drug causing aspirin resistance (AR).
Objectives:
To realize a systematic literature review to determine the impact of genetic variants on AR.
Methods:
Articles published in the MEDLINE/PubMed, Cochrane, Scopus, LILACS, and SCIELO databases were systematically screened. A total of 290 articles were identified and 269 articles were excluded because they did not comply with the previously established inclusion criteria. A total of 20 case-control studies and 1 cohort was included.
Results:
The genetic variants rs1126643 (ITGA2), rs3842787 (PTGS1), rs20417 (PTGS2), and rs5918 (ITGB3) were the most studied. As for relevance, of the 64 genetic variants evaluated by the articles, 14 had statistical significance (p < 0.05; 95% confidence interval [CI]) in at least one article. Among them, the following have had unanimous results: rs1371097 (P2RY1), rs1045642 (MDR1), rs1051931 and rs7756935 (PLA2G7), rs2071746 (HO1), rs1131882 and rs4523 (TBXA2R), rs434473 (ALOX12), rs9315042 (ALOX5AP), and rs662 (PON1), while these differ in real interference in AR: rs5918 (ITGB3), rs2243093 (GP1BA), rs1330344 (PTGS1), and rs20417 (PTGS2). As study limitations, we highlight the nonuniform methodologies of the analyzed articles and population differences.
Conclusion:
It is noteworthy that pharmacogenetics is an expanding area. Therefore, further studies are needed to better understand the association between genetic variants and AR.
More Related Videos
Related Concept Videos
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Drug Response: Overview
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

